These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 10860785)

  • 21. Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease.
    Baloyannis SJ; Costa V; Baloyannis IS
    J Neurol Sci; 2006 Oct; 248(1-2):35-41. PubMed ID: 16753180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Executive dysfunction in Parkinson's disease is associated with altered pallidal-frontal processing.
    Dirnberger G; Frith CD; Jahanshahi M
    Neuroimage; 2005 Apr; 25(2):588-99. PubMed ID: 15784438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
    Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
    Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients.
    Chiba-Falek O; Lopez GJ; Nussbaum RL
    Mov Disord; 2006 Oct; 21(10):1703-8. PubMed ID: 16795004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Localization of CKII beta subunits in Lewy bodies of Parkinson's disease.
    Ryu MY; Kim DW; Arima K; Mouradian MM; Kim SU; Lee G
    J Neurol Sci; 2008 Mar; 266(1-2):9-12. PubMed ID: 17884098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy.
    Lorenzl S; Albers DS; Chirichigno JW; Augood SJ; Beal MF
    J Neurol Sci; 2004 Mar; 218(1-2):39-45. PubMed ID: 14759631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
    Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
    Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of stroke in Parkinson's disease: a postmortem study.
    Mastaglia FL; Johnsen RD; Kakulas BA
    Mov Disord; 2002 Jul; 17(4):772-4. PubMed ID: 12210874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutathione peroxidase activity in Parkinson's disease brain.
    Kish SJ; Morito C; Hornykiewicz O
    Neurosci Lett; 1985 Aug; 58(3):343-6. PubMed ID: 4047494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.
    Knott C; Stern G; Wilkin GP
    Mol Cell Neurosci; 2000 Dec; 16(6):724-39. PubMed ID: 11124893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential bioactivated neurotoxicants, N-methylated beta-carbolinium ions, are present in human brain.
    Matsubara K; Collins MA; Akane A; Ikebuchi J; Neafsey EJ; Kagawa M; Shiono H
    Brain Res; 1993 Apr; 610(1):90-6. PubMed ID: 8518935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-methylation of pyridines and Parkinson's disease.
    Williams AC; Pall HS; Steventon GB; Green S; Buttrum S; Molloy H; Waring RH
    Adv Neurol; 1993; 60():194-6. PubMed ID: 8420135
    [No Abstract]   [Full Text] [Related]  

  • 36. Human brain phenolsulfotransferase. Regional distribution in Parkinson's disease.
    Baran H; Jellinger K
    J Neural Transm Park Dis Dement Sect; 1992; 4():267-76. PubMed ID: 1388697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-methylation underlying Parkinson's disease.
    Matsubara K; Aoyama K; Suno M; Awaya T
    Neurotoxicol Teratol; 2002; 24(5):593-8. PubMed ID: 12200190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra.
    Saggu H; Cooksey J; Dexter D; Wells FR; Lees A; Jenner P; Marsden CD
    J Neurochem; 1989 Sep; 53(3):692-7. PubMed ID: 2760616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel S-adenosylmethionine-dependent indole-N-methylation of beta-carbolines in brain particulate fractions.
    Matsubara K; Neafsey EJ; Collins MA
    J Neurochem; 1992 Aug; 59(2):511-8. PubMed ID: 1629724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease.
    Parsons RB; Smith SW; Waring RH; Williams AC; Ramsden DB
    Neurosci Lett; 2003 May; 342(1-2):13-6. PubMed ID: 12727306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.